KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla,Radhakrishnan Ramchandren,Armando Santoro,Ewa Paszkiewicz-Kozik,Robin E. Gasiorowski,Nathalie A. Johnson,Vladimir Y. Melnichenko,Laura Fogliatto,Iara Zapparoli Goncalves,José de Oliveira,Valeria Buccheri,Guilherme Fleury Perini,Neta Goldschmidt,Sergey Alekseev,Iryna Kryachok,Naohiro Sekiguchi,Ying Zhu,Akash Nahar,Patricia Marinello,Pier Luigi Zinzani

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

2020

8005Background: PD-1 blockade via pembro monotherapy showed antitumor activity in R/R cHL. KEYNOTE-204 (NCT02684292) was a randomized, international, open-label, phase III study of pembro vs BV in ...

Keywords:

Oncology
Blockade
Refractory
hodgkin lymphoma
Pembrolizumab
Internal medicine
Pathology
Brentuximab vedotin
open label
antitumor activity
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations